Centogene: peers
Centogene beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
Centogene, NanoRepro AG, Mdxhealth SA, Predilife S.A., Biocartis Group NV, Renalytix plc: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | Centogenebase 39K.F · 🇩🇪 DE Percentile in Healthcare Percentile in Germany | NanoRepro AG NN6.DE · 🇩🇪 DE Percentile in Healthcare Percentile in Germany | Mdxhealth SA MDXH · 🇧🇪 BE Percentile in Healthcare Percentile in Belgium | Predilife S.A. ALPRE.PA · 🇫🇷 FR Percentile in Healthcare Percentile in France | Biocartis Group NV 8XB.F · 🇧🇪 BE Percentile in Healthcare Percentile in Belgium | OneMedNet Corp ONMD · 🇬🇧 GB Percentile in Healthcare Percentile in UK | Star Equity Holdings, Inc. STRR · 🇺🇸 US Percentile in Healthcare Percentile in USA | Renalytix plc RNLXY · 🇬🇧 GB Percentile in Healthcare Percentile in UK | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $28 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one4th of 8 | $28 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one4th of 8 | $42 MAug 1, 2026 · Market data1st of 8 | $23 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one7th of 8 | $37 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one3rd of 8 | $27 MOct 30, 2026 · Market data6th of 8 | $37 MOct 15, 2026 · Market data2nd of 8 | $21 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one8th of 8 | $28 M8 ranked |
| Revenue (Better neither way: ranked highest first) | —— | —— | $108 MFY2025 · SEC2nd of 5 | —— | $51 MFY2023 · ESEF3rd of 5 | $1 MFY2025 · SEC5th of 5 | $172 MFY2025 · SEC1st of 5 | $2 MFY2024 · SEC4th of 5 | $51 M5 ranked |
| Net income (Higher is better) | —— | —— | $-34 MFY2025 · SEC5th of 5 | —— | $20 MFY2023 · ESEF1st of 5 | $-3 MFY2025 · SEC2nd of 5 | $-6 MFY2025 · SEC3rd of 5 | $-33 MFY2024 · SEC4th of 5 | $-6 M5 ranked |
| Employees (Better neither way: ranked highest first) | —— | —— | 364December 31, 2025 · Profile2nd of 2 | —— | —— | —— | 1,200December 31, 2025 · Profile1st of 2 | —— | 7822 ranked |
| Growth | |||||||||
| Revenue growth (Higher is better) | ———— | ———— | +19.8%FY2025 · SEC3rd of 468th86th | ———— | ———— | +112.5%FY2025 · SEC1st of 493rd99th | +22.9%FY2025 · SEC2nd of 472nd81st | -32.6%FY2024 · SEC4th of 47th1st | +21.4%4 ranked |
| Revenue growth, 3 years a year (Higher is better) | ———— | ———— | +42.8%FY2025 · SEC1st of 487th— | ———— | ———— | +5.8%FY2025 · SEC3rd of 444th50th | -5.0%FY2025 · SEC4th of 417th18th | +15.4%FY2024 · SEC2nd of 465th78th | +10.6%4 ranked |
| Margins and returns | |||||||||
| Gross margin (Higher is better) | ———— | ———— | 64.5%FY2025 · SEC1st of 459th98th | ———— | ———— | -36.8%FY2025 · SEC4th of 41st1st | 46.4%FY2025 · SEC2nd of 432nd59th | 7.0%FY2024 · SEC3rd of 44th5th | 26.7%4 ranked |
| Operating margin (Higher is better) | ———— | ———— | -13.4%FY2025 · SEC2nd of 345th10th | ———— | ———— | -711.0%FY2025 · SEC3rd of 33rd0th | -2.1%FY2025 · SEC1st of 355th36th | ———— | -13.4%3 ranked |
| Net margin (Higher is better) | ———— | ———— | -31.1%FY2025 · SEC2nd of 338th7th | ———— | ———— | -205.9%FY2025 · SEC3rd of 315th2nd | -3.4%FY2025 · SEC1st of 356th36th | ———— | -31.1%3 ranked |
| Free cash flow margin (Higher is better) | ———— | ———— | -3.1%FY2025 · SEC1st of 347th25th | ———— | ———— | -552.2%FY2025 · SEC3rd of 36th1st | -5.2%FY2025 · SEC2nd of 345th25th | ———— | -5.2%3 ranked |
| Return on equity (Higher is better) | ———— | ———— | ———— | ———— | ———— | ———— | -11.2%FY2025 · SEConly one with it66th33rd | ———— | -11.2%— |
| Valuation | |||||||||
| Price to sales (Better neither way: ranked highest first) | ———— | ———— | 0.4׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | ———— | 11.8×price Oct 30, 2026 · Market data1st of 276th97th | 0.2×price Oct 15, 2026 · Market data2nd of 22nd4th | ———— | 6.0×2 ranked |
| Price to book (Better neither way: ranked highest first) | ———— | ———— | ———— | ———— | ———— | ———— | 0.6×price Oct 15, 2026 · Market dataonly one with it8th8th | ———— | 0.6×— |
| Free cash flow yield (Higher is better) | ———— | ———— | -8.0%†price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | ———— | -27.7%price Oct 30, 2026 · Market data2nd of 227th11th | -24.2%price Oct 15, 2026 · Market data1st of 230th13th | ———— | -26.0%2 ranked |
| Financial strength | |||||||||
| Debt to equity (Lower is better) | ———— | ———— | ———— | ———— | ———— | ———— | 0.1×FY2025 · SEConly one with it19th14th | ———— | 0.1×— |
| Interest cover (Higher is better) | ———— | ———— | ———— | ———— | ———— | -138.1×FY2025 · SEConly one with it11th3rd | ———— | ———— | -138.1×— |
| Piotroski F-score (Higher is better) | —— | —— | —— | —— | —— | 6 of 9FY2025 · SEC1st of 2 | 1 of 9FY2025 · SEC2nd of 2 | —— | 3.5 of 92 ranked |
| Scorecard | |||||||||
| Scorecard (Higher is better) | —— | —— | 5 of 11FY2025 · Scorecard1st of 4 | —— | —— | 4 of 19FY2025 · Scorecard4th of 4 | 8 of 24FY2025 · Scorecard2nd of 4 | 3 of 10FY2024 · Scorecard3rd of 4 | 32% passed4 ranked |
| Valuation checks (Higher is better) | —— | —— | —— | —— | —— | 0 of 5FY2025 · Scorecard2nd of 2 | 2 of 5FY2025 · Scorecard1st of 2 | —— | 20% passed2 ranked |
| Growth checks (Higher is better) | —— | —— | 4 of 6FY2025 · Scorecard2nd of 4 | —— | —— | 3 of 4FY2025 · Scorecard1st of 4 | 1 of 6FY2025 · Scorecard4th of 4 | 3 of 5FY2024 · Scorecard3rd of 4 | 63% passed4 ranked |
| Profitability checks (Higher is better) | —— | —— | 1 of 4FY2025 · Scorecard1st of 4 | —— | —— | 0 of 4FY2025 · Scorecard3rd of 4 | 1 of 5FY2025 · Scorecard2nd of 4 | 0 of 2FY2024 · Scorecard3rd of 4 | 10% passed4 ranked |
| Financial health checks (Higher is better) | —— | —— | 0 of 1FY2025 · Scorecard3rd of 4 | —— | —— | 1 of 5FY2025 · Scorecard2nd of 4 | 3 of 5FY2025 · Scorecard1st of 4 | 0 of 2FY2024 · Scorecard3rd of 4 | 10% passed4 ranked |
| Shareholder returns checks (Higher is better) | —— | —— | —— | —— | —— | 0 of 1FY2025 · Scorecard2nd of 3 | 1 of 3FY2025 · Scorecard1st of 3 | 0 of 1FY2024 · Scorecard2nd of 3 | 0% passed3 ranked |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | —— | —— | 44.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 3 | —— | —— | 2.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 3 | 25.0%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 3 | —— | 25.0%3 ranked |
| Institutions holding (Better neither way: ranked highest first) | —— | —— | 242026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 3 | —— | —— | 132026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 3 | 242026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 3 | —— | 243 ranked |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | —— | —— | -31.5 pp2026-Q2 against 2026-Q1 · 13F2nd of 2 | —— | —— | —— | +0.8 pp2026-Q2 against 2026-Q1 · 13F1st of 2 | —— | -15.4 pp2 ranked |
| Dividends | |||||||||
| Shareholder yield (Higher is better) | ———— | ———— | ———— | ———— | ———— | ———— | 7.1%FY2025 · SEConly one with it84th80th | ———— | 7.1%— |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
† The market cap behind this figure is more than 60 days old (no market-data feed for that exchange yet): it is shown but not ranked or given a percentile.
Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Centogene: How market caps are worked out; NanoRepro AG: How market caps are worked out; Mdxhealth SA: How market caps are worked out; Predilife S.A.: How market caps are worked out; Biocartis Group NV: How market caps are worked out; OneMedNet Corp: How market caps are worked out; Star Equity Holdings, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Renalytix plc: How market caps are worked out.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| Centogene | — | — | — |
| NanoRepro AG | — | — | — |
| Mdxhealth SA | -13.4%FY2025 | 45th percentile in Healthcaremedian -7.8%, 678 companies | 10th percentile in Belgiummedian 7.5%, 36 companies |
| Predilife S.A. | — | — | — |
| Biocartis Group NV | — | — | — |
| OneMedNet Corp | -711.0%FY2025 | 3rd percentile in Healthcaremedian -7.8%, 678 companies | 0th percentile in UKmedian 8.5%, 313 companies |
| Star Equity Holdings, Inc. | -2.1%FY2025 | 55th percentile in Healthcaremedian -7.8%, 678 companies | 36th percentile in USAmedian 3.4%, 2,607 companies |
| Renalytix plc | — | — | — |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | Centogene | NanoRepro AG | Mdxhealth SA | Predilife S.A. | Biocartis Group NV | OneMedNet Corp | Star Equity Holdings, Inc. | Renalytix plc |
|---|---|---|---|---|---|---|---|---|
| 2025 | — | — | $108 MSEC2nd | — | — | $1 MSEC3rd | $172 MSEC1st | — |
| 2024 | — | — | $90 MSEC2nd | — | — | $1 MSEC4th | $140 MSEC1st | $2 MSEC3rd |
| 2023 | — | — | $70 MSEC2nd | — | $51 MESEF3rd | $1 MSEC5th | $161 MSEC1st | $3 MSEC4th |
| 2022 | — | — | $37 MSEC3rd | — | $60 MESEF2nd | $1 MSEC5th | $201 MSEC1st | $3 MSEC4th |
| 2021 | — | — | $22 MSEC2nd | — | — | — | $169 MSEC1st | $1 MSEC3rd |
| 2020 | — | — | $18 MSEC2nd | — | — | — | $101 MSEC1st | — |
| 2019 | — | — | $12 MSEC2nd | — | — | — | $94 MSEC1st | — |
| 2018 | — | — | — | — | — | — | $67 MSEC | — |
| 2017 | — | — | — | — | — | — | $457 MSEC | — |
| 2016 | — | — | — | — | — | — | $423 MSEC | — |
| 2015 | — | — | — | — | — | — | $463 MSEC | — |
| 2014 | — | — | — | — | — | — | $581 MSEC | — |
Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of Centogene#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- NanoRepro AGNN6.DE · 🇩🇪 GermanySame industry: Diagnostics and Research · Similar size: $28 M market cap against $28 M · Same country: GermanyMarket cap $28 M (last known, Jan 5, 2024)95 of 100 (industry or sector 50 + size 30 + country 15)In the group
- Mdxhealth SAMDXH · 🇧🇪 BelgiumSame industry: Diagnostics and Research · Similar size: $42 M market cap against $28 M · Same region: Western Europe · Ratios of the last two fiscal years on fileMarket cap $42 M (Aug 1, 2026) · revenue $108 M (year to December 2025)89 of 100 (industry or sector 50 + size 27 + country 7 + figures on file 5)In the group
- Predilife S.A.ALPRE.PA · 🇫🇷 FranceSame industry: Diagnostics and Research · Similar size: $23 M market cap against $28 M · Same region: Western EuropeMarket cap $23 M (last known, Jan 5, 2024)86 of 100 (industry or sector 50 + size 29 + country 7)In the group
- Biocartis Group NV8XB.F · 🇧🇪 BelgiumSame industry: Diagnostics and Research · Similar size: $37 M market cap against $28 M · Same region: Western EuropeMarket cap $37 M (last known, Jul 30, 2023) · revenue $51 M (year to December 2023)85 of 100 (industry or sector 50 + size 28 + country 7)In the group
- OneMedNet CorpONMD · 🇬🇧 UKSame industry: Diagnostics and Research · Similar size: $27 M market cap against $28 M · Ratios of the last two fiscal years on fileMarket cap $27 M (Oct 30, 2026) · revenue $1 M (year to December 2025)85 of 100 (industry or sector 50 + size 30 + figures on file 5)In the group
- Star Equity Holdings, Inc.STRR · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $37 M market cap against $28 M · Ratios of the last two fiscal years on fileMarket cap $37 M (Oct 15, 2026) · revenue $172 M (year to December 2025)83 of 100 (industry or sector 50 + size 28 + figures on file 5)In the group
- Renalytix plcRNLXY · 🇬🇧 UKSame industry: Diagnostics and Research · Similar size: $21 M market cap against $28 M · Ratios of the last two fiscal years on fileMarket cap $21 M (last known, Jan 5, 2024) · revenue $2 M (year to June 2024)83 of 100 (industry or sector 50 + size 28 + figures on file 5)In the group
- Precipio, Inc.PRPO · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $38 M market cap against $28 M · Ratios of the last two fiscal years on fileMarket cap $38 M (Oct 22, 2026) · revenue $53 M (year to December 2025)83 of 100 (industry or sector 50 + size 28 + figures on file 5)+ Add
- Novacyt S.A.ALNOV.PA · 🇫🇷 FranceSame industry: Diagnostics and Research · Similar size: $55 M market cap against $28 M · Same region: Western EuropeMarket cap $55 M (last known, Jan 5, 2024) · revenue $385 M83 of 100 (industry or sector 50 + size 26 + country 7)+ Add
- DarioHealth Corp.DRIO · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $42 M market cap against $28 M · Ratios of the last two fiscal years on fileMarket cap $42 M (Oct 22, 2026) · revenue $22 M (year to December 2025)82 of 100 (industry or sector 50 + size 27 + figures on file 5)+ Add
- Epigenomics AGEPGNF · 🇩🇪 GermanySame industry: Diagnostics and Research · 7.0× smaller by market cap · Same country: GermanyMarket cap $4 M (last known, Jul 30, 2023)82 of 100 (industry or sector 50 + size 17 + country 15)+ Add
- Bionano Genomics, Inc.BNGO · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $17 M market cap against $28 M · Ratios of the last two fiscal years on fileMarket cap $17 M (Oct 30, 2026) · revenue $29 M (year to December 2025)82 of 100 (industry or sector 50 + size 27 + figures on file 5)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.